PURPOSE: To assess the impact of micropapillary histological variant on oncological outcome after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinomas (UTUCs). METHODS: A French multicenter retrospective study was performed on patients who underwent RNU between 1995 and 2010. Pathological reports were reviewed to identify patients with pure urothelial carcinomas (PUC) and those with micropapillary histological variant (MPC). Uni- and multivariate Cox regression analyses were performed to identify factors predictive of survival. RESULTS: Overall, 519 patients were included and divided into two groups: 480 PUC and 39 MPC. Median follow-up were 28 and 19 months, respectively (p = 0.63). There was no difference between the two groups for gender, age and tumor location (pelvicalyceal or ureteral). MPC was associated with high-stage and high-grade UTUC (p < 0.001 and 0.04). No difference was observed between the two groups for 5-year cancer-specific survival (76.1 vs. 88.2 %; p = 0.54). The 5-year metastasis-free survival was significantly lower in the MPC group (48.9 vs. 73.8 %; p = 0.037). In multivariate analysis, pT stage, lymphovascular invasion, margin status and adjuvant chemotherapy administration were independent predictors of specific survival (p = 0.002; 0.001; 0.02; 0.01), contrary to histological variant (p = 0.94). CONCLUSIONS: Micropapillary histological variant was associated with advanced UTUC and reduced metastasis-free survival after RNU. It should be considered as an aggressive tumor and thus be stated in any pathological report after radical surgery.
PURPOSE: To assess the impact of micropapillary histological variant on oncological outcome after radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinomas (UTUCs). METHODS: A French multicenter retrospective study was performed on patients who underwent RNU between 1995 and 2010. Pathological reports were reviewed to identify patients with pure urothelial carcinomas (PUC) and those with micropapillary histological variant (MPC). Uni- and multivariate Cox regression analyses were performed to identify factors predictive of survival. RESULTS: Overall, 519 patients were included and divided into two groups: 480 PUC and 39 MPC. Median follow-up were 28 and 19 months, respectively (p = 0.63). There was no difference between the two groups for gender, age and tumor location (pelvicalyceal or ureteral). MPC was associated with high-stage and high-grade UTUC (p < 0.001 and 0.04). No difference was observed between the two groups for 5-year cancer-specific survival (76.1 vs. 88.2 %; p = 0.54). The 5-year metastasis-free survival was significantly lower in the MPC group (48.9 vs. 73.8 %; p = 0.037). In multivariate analysis, pT stage, lymphovascular invasion, margin status and adjuvant chemotherapy administration were independent predictors of specific survival (p = 0.002; 0.001; 0.02; 0.01), contrary to histological variant (p = 0.94). CONCLUSIONS: Micropapillary histological variant was associated with advanced UTUC and reduced metastasis-free survival after RNU. It should be considered as an aggressive tumor and thus be stated in any pathological report after radical surgery.
Authors: Claudio Jeldres; Maxine Sun; Hendrik Isbarn; Giovanni Lughezzani; Lars Budäus; Ahmed Alasker; Shahrohk F Shariat; Jean-Baptiste Lattouf; Hugues Widmer; Daniel Pharand; Philippe Arjane; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Urology Date: 2009-12-06 Impact factor: 2.649
Authors: Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard Sylvester; Max Burger; Nigel Cowan; Andreas Böhle; Bas W G Van Rhijn; Eero Kaasinen; Joan Palou; Shahrokh F Shariat Journal: Eur Urol Date: 2013-03-19 Impact factor: 20.096
Authors: Ankur R Sangoi; Andrew H Beck; Mahul B Amin; Liang Cheng; Jonathan I Epstein; Donna E Hansel; Kenneth A Iczkowski; Antonio Lopez-Beltran; Esther Oliva; Gladell P Paner; Victor E Reuter; Jae Y Ro; Rajal B Shah; Steven S Shen; Pheroze Tamboli; Jesse K McKenney Journal: Am J Surg Pathol Date: 2010-09 Impact factor: 6.394
Authors: Adrian S Fairey; Siamak Daneshmand; Lina Wang; Anne Schuckman; Gary Lieskovsky; Hooman Djaladat; Jie Cai; Gus Miranda; Eila C Skinner Journal: Urol Oncol Date: 2013-03-14 Impact factor: 3.498
Authors: Pierre Colin; Adil Ouzzane; David R Yates; François Audenet; Audenet François; Géraldine Pignot; Alexis Arvin-Berod; Olivier Merigot de Treigny; Guy Laurent; Antoine Valeri; Jacques Irani; Irani Jacques; Fabien Saint; Solène Gardic; Pascal Gres; François Rozet; Yann Neuzillet; Alain Ruffion; Morgan Rouprêt Journal: Ann Surg Oncol Date: 2012-07-28 Impact factor: 5.344
Authors: Jeffrey K Wang; Stephen A Boorjian; John C Cheville; Simon P Kim; Robert F Tarrell; Prabin Thapa; Igor Frank Journal: World J Urol Date: 2012-11-07 Impact factor: 4.226
Authors: Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat Journal: World J Urol Date: 2016-04-21 Impact factor: 4.226
Authors: Jonathan J Duplisea; Firas G Petros; Roger Li; Bryan Fellman; Charles C Guo; Bogdan A Czerniak; Arlene O Siefker-Radtke; John C Araujo; Colin P N Dinney; Surena F Matin Journal: Urol Oncol Date: 2019-02-16 Impact factor: 3.498
Authors: Alexandra Masson-Lecomte; Evanguelos Xylinas; Morgane Bouquot; Mathilde Sibony; Yves Allory; Eva Comperat; Marc Zerbib; Alexandre de la Taille; Morgan Rouprêt Journal: World J Urol Date: 2014-09-02 Impact factor: 4.226
Authors: Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat Journal: Transl Androl Urol Date: 2016-10
Authors: Wojciech Polom; Wojciech Cytawa; Anna Polom; Mikołaj Frankiewicz; Edyta Szurowska; Piotr Lass; Marcin Matuszewski Journal: J Clin Med Date: 2021-11-23 Impact factor: 4.241